The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers.
Joyce Liu
No relevant relationships to disclose
Isabelle Laure Ray-Coquard
No relevant relationships to disclose
Frédéric Selle
No relevant relationships to disclose
Andres Poveda
No relevant relationships to disclose
David Cibula
No relevant relationships to disclose
Hal W. Hirte
No relevant relationships to disclose
Francesco Raspagliesi
No relevant relationships to disclose
Laurence Gladieff
No relevant relationships to disclose
Philipp Harter
Consultant or Advisory Role - Roche
Honoraria - Roche
Ilaria Schiavetto
No relevant relationships to disclose
Isabelle Marie Tabah-Fisch
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Gavin MacBeath
Employment or Leadership Position - Merrimack Pharmaceuticals
Stock Ownership - Merrimack Pharmaceuticals
Akos Gabor Czibere
Employment or Leadership Position - Merrimack Pharmaceuticals
Stock Ownership - Merrimack Pharmaceuticals
R. Wendel Naumann
No relevant relationships to disclose
Robert L. Coleman
No relevant relationships to disclose
Ignace Vergote
No relevant relationships to disclose
Eric Pujade-Lauraine
No relevant relationships to disclose